News By Tag
* Market Forecast
* Unmet Need
* Clinical Trials
* Marketed Products
* More Tags...
News By Place
Pulmonary Arterial Hypertension (PAH) Therapeutics - Global Drug Forecasts and Treatment Analysis to
Aarkstore announce a new report "Pulmonary Arterial Hypertension (PAH) Therapeutics - Global Drug Forecasts and Treatment Analysis to 2020 " through its vast collection of market research report.
This report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GlobalData's team of industry experts.
GlobalData estimated the global PAH therapeutics market was worth around $3.3 billion in 2011, having grown at a Compound Annual Growth Rate (CAGR) of 38.6% from 2002 to 2011. PAH is a rare indication but despite the small patient volume, the market showed a tremendous growth in the historic period. This growth was due to the significant drug development activity corresponding to the launch of around eight premium priced drugs in the PAH therapeutics market from 2002 to 2011. Patient volume also increased during this period due to the increasing awareness.
The drugs used in the treatment of PAH are Tracleer (bosentan), Letairis (ambrisentan)
The global PAH therapeutics market is estimated to be worth $3.1 billion in 2020. It is forecast to show a negative CAGR of 0.6% from 2011 to 2020.
In 2011, the leading drugs in G7 market (the US, France, Germany, Italy, Spain, the UK and Japan) were Tracleer, Revatio, Letairis/Volibris and Remodulin with sales of $1,303.3m, $439.0m, $364.3m and $363.7m respectively.
For more information, please visit:
Or email us at email@example.com or call +918149852585
Pulmonary Arterial Hypertension (PAH) Therapeutics - Global Drug Forecasts and Treatment Analysis to 2020
Pulmonary Arterial Hypertension Global Clinical Trials Review, H2, 2011
Pulmonary Arterial Hypertension - Pipeline Review, H2 2011
Withdrawal of Sitaxentan (Thelin) Creates Huge Unmet Need in the Pulmonary Arterial Hypertension (PAH) Market
Pulmonary Arterial Hypertension - Pipeline Review, Q4 2010
Pulmonary Arterial Hypertension Global Clinical Trials Review, Q4, 2010
Pulmonary Arterial Hypertension (PAH) - Pipeline Assessment and Market Forecasts to 2016
Pulmonary Arterial Hypertension (PAH) - Drug Pipeline Analysis and Market Forecasts to 2016
Stakeholder Opinions: Pulmonary Arterial Hypertension clinical community builds order from chaos
Tel : +912227453309
Email : firstname.lastname@example.org
Website : http://www.aarkstore.com
Follow us on twitter: http://twitter.com/
# # #
Aarkstore Enterprise specialize in providing online market business information on market research reports, books, magazines, conference booking at competitive prices, and strive to provide excellent and innovative service to our customers.